Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Charles L. Pope CPA | Executive Chairman | 112.5k | -- | 1952 |
| Ms. Janet Huffman | Interim CEO, President, CFO, Secretary & Treasurer | 332.5k | -- | 1973 |
| Mr. Greg Gironda | Head of Business Development | -- | -- | -- |
| Dr. James P. Kelly M.A., M.D. | Chief Medical Officer | -- | -- | -- |
| Dr. William Franklin Peacock IV, F.A.C.E.P., FACC, M.D. | Chief Clinical Officer | -- | -- | -- |
Oragenics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 3
Description
Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
Corporate Governance
Upcoming Events
May 13, 2025 at 5:00 PM UTC - May 19, 2025 at 5:00 PM UTC
Oragenics, Inc. Earnings Date